Table 4.
Demographics and baseline characteristics of critically ill patients (n=89)
| Characteristics | All patients (n=89) |
Survivors (n=47) |
Non-survivors (n=42) |
P value |
| Male | 61 (68.5) | 30 (63.8) | 31 (73.8) | 0.365 |
| Age (year) | 66.0 (14.2)* | 69.1 (12.5)* | 63.3 (15.2)* | 0.052 |
| SOFA score*† | 4.3 (2.0) | 3.6 (1.7) | 5.1 (1.9) | <0.001‡ |
| Ethnicity | ||||
| Caucasian | 47 (52.8) | 25 (53.2) | 22 (52.4) | |
| African-American | 25 (28.1) | 12 (25.5) | 13 (31.0) | |
| Hispanic/Latino | 12 (13.5) | 8 (17.0) | 4 (9.5) | 0.685 |
| Asian | 5 (5.6) | 2 (4.3) | 3 (7.1) | |
| Others | – | – | – | |
| Treatment | ||||
| Azithromycin | 69 (77.5) | 34 (72.3) | 35 (83.3) | 0.215 |
| Hydroxychloroquine | 42 (47.2) | 23 (48.9) | 19 (45.2) | 0.727 |
| Steroids | 39 (43.8) | 19 (40.4) | 20 (47.6) | 0.495 |
| Ascorbic acid | 39 (43.8) | 22 (46.8) | 17 (40.5) | 0.548 |
| Zinc | 40 (44.9) | 21 (44.7) | 19 (45.2) | 0.958 |
| Tocilizumab | 11 (12.4) | 5 (10.6) | 6 (14.3) | 0.750 |
| Convalescent plasma | 30 (33.7) | 14 (29.8) | 16 (38.1) | 0.408 |
| Remdesivir | 11 (12.4) | 6 (12.8) | 5 (11.9) | 1.000 |
| Complications | ||||
| Acute kidney injury | 56 (62.9) | 22 (46.8) | 34 (81.0) | 0.001‡ |
| ARDS | 47 (52.8) | 15 (31.9) | 32 (76.2) | <0.001‡ |
| Arrhythmias | 21 (23.6) | 10 (21.3) | 11 (26.2) | 0.586 |
| QT prolongation | 16 (18.0) | 10 (21.3) | 6 (14.3) | 0.391 |
| Venous thromboembolism | 5 (5.6) | 3 (6.4) | 2 (4.8) | 1.000 |
| Hospital stay (day) | 13.1 (9.6)* | 10.4 (8.1)* | 15.5 (10.3)* | 0.125 |
| Outcome | ||||
| Recovery/discharge | 43 (48.3) | |||
| Remained hospitalised | 2 (2.2) | |||
| Death | 42 (47.2) |
*Mean (SD).
†Collected on the first day of ICU admission.
‡Statistically significant.
ARDS, acute respiratory distress syndrome; ICU, intensive care unit; SOFA, Sequential Organ Failure Assessment.